Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Aurinia Pharmaceuticals reported revenue of $283M in the fiscal year ended Dec 2025, up 20.4% from the year before. Operating income was $105M, an operating margin of 37.1%, and net income was $287M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.6 | 134 | 176 | 235 | 283 |
| Cost of revenue | 1.1 | 5.7 | 14.1 | 28.2 | 32.7 |
| Gross profit | 44.5 | 128 | 161 | 207 | 250 |
| Research & development | 51.1 | 45.0 | 49.6 | 20.8 | 32.5 |
| Selling, general & admin | 174 | 196 | 195 | – | – |
| Operating income | −181 | −111 | −91.7 | −4.7 | 105 |
| Interest expense | 0.0 | 0.0 | 2.8 | 4.8 | 4.3 |
| Pre-tax income | −180 | −106 | −77.5 | 7.4 | 114 |
| Income tax | 0.8 | 1.8 | 0.6 | 1.7 | −173 |
| Net income | −181 | −108 | −78.0 | 5.8 | 287 |
| Diluted EPS | −1.40 | −0.76 | −0.54 | 0.04 | 2.07 |
| Diluted shares | 129 | 142 | 143 | 146 | 139 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 232 | 94.1 | 48.8 | 83.4 | 80.2 |
| Receivables | 15.4 | 13.5 | 24.1 | 36.5 | 41.5 |
| Inventory | 19.3 | 24.8 | 39.7 | 39.2 | 45.7 |
| Current assets | 513 | 443 | 425 | 447 | 492 |
| Net PP&E | 4.4 | 3.7 | 3.4 | 2.7 | 2.1 |
| Total assets | 543 | 471 | 548 | 551 | 752 |
| Payables | 3.9 | 3.1 | 4.3 | 5.2 | 3.3 |
| Deferred revenue | 0.2 | 3.1 | 4.8 | 11.0 | 3.7 |
| Current liabilities | 40.6 | 46.1 | 77.2 | 97.8 | 93.7 |
| Total liabilities | 64.3 | 65.4 | 170 | 173 | 170 |
| Shareholders' equity | 479 | 405 | 378 | 377 | 581 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −158 | −79.5 | −33.5 | 44.4 | 136 |
| Depreciation & amortisation | 2.8 | 2.7 | 11.6 | 19.4 | 19.4 |
| Stock-based compensation | 31.2 | 32.3 | 45.3 | 31.6 | 14.7 |
| Share buybacks | – | 0.0 | 0.0 | 40.2 | 98.2 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 193.9% | 31.0% | 34.0% | 20.4% |
| EPS growth (YoY) | – | – | – | – | 5075.0% |
| Gross margin | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating margin | −396.3% | −83.2% | −52.2% | −2.0% | 37.1% |
| Net margin | −396.8% | −80.7% | −44.5% | 2.4% | 101.5% |
| Return on equityBlank when equity is negative | −37.8% | −26.7% | −20.6% | 1.5% | 49.4% |
| ROCEEBIT ÷ (assets − current liabilities) | −36.0% | −26.2% | −19.5% | −1.0% | 15.9% |
| Cash conversion (CFO ÷ net income) | 0.87x | 0.74x | 0.43x | 7.72x | 0.47x |
| Receivable days | 123 | 37 | 50 | 57 | 53 |
| Inventory days | 6466 | 1595 | 1024 | 507 | 511 |
| Payable days | 1298 | 199 | 112 | 67 | 37 |
| Interest cover | – | – | −33.0x | −0.97x | 24.2x |
| Current ratio | 12.6x | 9.60x | 5.50x | 4.57x | 5.25x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.